Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 17, 2024

BUY
$32.18 - $46.57 $1.26 Million - $1.83 Million
39,208 Added 12.15%
361,846 $16.3 Million
Q3 2023

Oct 13, 2023

BUY
$44.2 - $50.2 $14.3 Million - $16.2 Million
322,638 New
322,638 $14.7 Million
Q1 2023

Apr 18, 2023

SELL
$45.44 - $74.26 $15.8 Million - $25.8 Million
-347,363 Reduced 49.26%
357,851 $23.5 Million
Q4 2022

Jan 31, 2023

BUY
$41.39 - $81.0 $11.1 Million - $21.6 Million
267,081 Added 60.96%
705,214 $31.7 Million
Q3 2022

Oct 14, 2022

BUY
$72.36 - $113.1 $5.72 Million - $8.94 Million
79,079 Added 22.02%
438,133 $31.7 Million
Q2 2022

Jul 27, 2022

BUY
$87.2 - $114.05 $5.23 Million - $6.84 Million
59,994 Added 20.06%
359,054 $38.5 Million
Q1 2022

Apr 28, 2022

BUY
$94.19 - $124.49 $797,977 - $1.05 Million
8,472 Added 2.92%
299,060 $33.2 Million
Q4 2021

Jan 25, 2022

SELL
$119.57 - $139.07 $9.79 Million - $11.4 Million
-81,903 Reduced 21.99%
290,588 $37.2 Million
Q3 2021

Oct 18, 2021

SELL
$109.17 - $142.35 $17.1 Million - $22.3 Million
-156,398 Reduced 29.57%
372,491 $49.6 Million
Q2 2021

Jul 16, 2021

BUY
$100.34 - $115.69 $6.97 Million - $8.04 Million
69,456 Added 15.12%
528,889 $57.2 Million
Q1 2021

Apr 26, 2021

BUY
$101.51 - $125.27 $1.37 Million - $1.69 Million
13,456 Added 3.02%
459,433 $48.4 Million
Q4 2020

Jan 26, 2021

BUY
$85.88 - $105.36 $984,957 - $1.21 Million
11,469 Added 2.64%
445,977 $46.4 Million
Q3 2020

Nov 09, 2020

BUY
$72.74 - $92.5 $4.07 Million - $5.18 Million
55,958 Added 14.78%
434,508 $37.2 Million
Q2 2020

Aug 12, 2020

BUY
$48.02 - $79.04 $2.47 Million - $4.06 Million
51,342 Added 15.69%
378,550 $27.7 Million
Q1 2020

May 13, 2020

BUY
$36.95 - $62.95 $12.1 Million - $20.6 Million
327,208 New
327,208 $17 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Tran Capital Management, L.P. Portfolio

Follow Tran Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tran Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Tran Capital Management, L.P. with notifications on news.